These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 19783548)
21. Compromised mitochondrial complex II in models of Machado-Joseph disease. Laço MN; Oliveira CR; Paulson HL; Rego AC Biochim Biophys Acta; 2012 Feb; 1822(2):139-49. PubMed ID: 22037589 [TBL] [Abstract][Full Text] [Related]
22. A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. Goti D; Katzen SM; Mez J; Kurtis N; Kiluk J; Ben-Haïem L; Jenkins NA; Copeland NG; Kakizuka A; Sharp AH; Ross CA; Mouton PR; Colomer V J Neurosci; 2004 Nov; 24(45):10266-79. PubMed ID: 15537899 [TBL] [Abstract][Full Text] [Related]
23. A fine balance between Prpf19 and Exoc7 in achieving degradation of aggregated protein and suppression of cell death in spinocerebellar ataxia type 3. Chen ZS; Huang X; Talbot K; Chan HYE Cell Death Dis; 2021 Feb; 12(2):136. PubMed ID: 33542212 [TBL] [Abstract][Full Text] [Related]
24. Potassium channel dysfunction and depolarized resting membrane potential in a cell model of SCA3. Jeub M; Herbst M; Spauschus A; Fleischer H; Klockgether T; Wuellner U; Evert BO Exp Neurol; 2006 Sep; 201(1):182-92. PubMed ID: 16765348 [TBL] [Abstract][Full Text] [Related]
25. Cerebellar soluble mutant ataxin-3 level decreases during disease progression in Spinocerebellar Ataxia Type 3 mice. Nguyen HP; Hübener J; Weber JJ; Grueninger S; Riess O; Weiss A PLoS One; 2013; 8(4):e62043. PubMed ID: 23626768 [TBL] [Abstract][Full Text] [Related]
26. Interaction of the polyglutamine protein ataxin-3 with Rad23 regulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3. Sutton JR; Blount JR; Libohova K; Tsou WL; Joshi GS; Paulson HL; Costa MDC; Scaglione KM; Todi SV Hum Mol Genet; 2017 Apr; 26(8):1419-1431. PubMed ID: 28158474 [TBL] [Abstract][Full Text] [Related]
27. Expression of expanded polyglutamine protein induces behavioral changes in Drosophila (polyglutamine-induced changes in Drosophila). Kim YT; Shin SM; Lee WY; Kim GM; Jin DK Cell Mol Neurobiol; 2004 Feb; 24(1):109-22. PubMed ID: 15049515 [TBL] [Abstract][Full Text] [Related]
28. T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse. Chou AH; Chen YL; Chiu CC; Yuan SJ; Weng YH; Yeh TH; Lin YL; Fang JM; Wang HL Neuropharmacology; 2015 Dec; 99():308-17. PubMed ID: 26254860 [TBL] [Abstract][Full Text] [Related]
29. Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Warrick JM; Morabito LM; Bilen J; Gordesky-Gold B; Faust LZ; Paulson HL; Bonini NM Mol Cell; 2005 Apr; 18(1):37-48. PubMed ID: 15808507 [TBL] [Abstract][Full Text] [Related]
30. Inflammatory genes are upregulated in expanded ataxin-3-expressing cell lines and spinocerebellar ataxia type 3 brains. Evert BO; Vogt IR; Kindermann C; Ozimek L; de Vos RA; Brunt ER; Schmitt I; Klockgether T; Wüllner U J Neurosci; 2001 Aug; 21(15):5389-96. PubMed ID: 11466410 [TBL] [Abstract][Full Text] [Related]
31. Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: conclusions from double-transgenic mouse models. Hübener J; Riess O Neurobiol Dis; 2010 Apr; 38(1):116-24. PubMed ID: 20079840 [TBL] [Abstract][Full Text] [Related]
32. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3. Schmidt J; Schmidt T; Golla M; Lehmann L; Weber JJ; Hübener-Schmid J; Riess O J Neurochem; 2016 Jul; 138(1):150-62. PubMed ID: 26990650 [TBL] [Abstract][Full Text] [Related]
33. Flanking domain stability modulates the aggregation kinetics of a polyglutamine disease protein. Saunders HM; Gilis D; Rooman M; Dehouck Y; Robertson AL; Bottomley SP Protein Sci; 2011 Oct; 20(10):1675-81. PubMed ID: 21780213 [TBL] [Abstract][Full Text] [Related]
34. Hsp104 suppresses polyglutamine-induced degeneration post onset in a drosophila MJD/SCA3 model. Cushman-Nick M; Bonini NM; Shorter J PLoS Genet; 2013; 9(9):e1003781. PubMed ID: 24039611 [TBL] [Abstract][Full Text] [Related]
35. SUMO-1 modification on K166 of polyQ-expanded ataxin-3 strengthens its stability and increases its cytotoxicity. Zhou YF; Liao SS; Luo YY; Tang JG; Wang JL; Lei LF; Chi JW; Du J; Jiang H; Xia K; Tang BS; Shen L PLoS One; 2013; 8(1):e54214. PubMed ID: 23382880 [TBL] [Abstract][Full Text] [Related]
36. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein. Ashraf NS; Sutton JR; Yang Y; Ranxhi B; Libohova K; Shaw ED; Barget AJ; Todi SV; Paulson HL; Costa MDC Neurobiol Dis; 2020 Apr; 137():104697. PubMed ID: 31783119 [TBL] [Abstract][Full Text] [Related]
37. Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machado-Joseph disease. Nascimento-Ferreira I; Nóbrega C; Vasconcelos-Ferreira A; Onofre I; Albuquerque D; Aveleira C; Hirai H; Déglon N; Pereira de Almeida L Brain; 2013 Jul; 136(Pt 7):2173-88. PubMed ID: 23801739 [TBL] [Abstract][Full Text] [Related]
38. HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3. Chou AH; Chen SY; Yeh TH; Weng YH; Wang HL Neurobiol Dis; 2011 Feb; 41(2):481-8. PubMed ID: 21047555 [TBL] [Abstract][Full Text] [Related]
39. Decreased protein synthesis of Hsp27 associated with cellular toxicity in a cell model of Machado-Joseph disease. Chang WH; Tien CL; Chen TJ; Nukina N; Hsieh M Neurosci Lett; 2009 Apr; 454(2):152-6. PubMed ID: 19429074 [TBL] [Abstract][Full Text] [Related]
40. Differential toxicity of ataxin-3 isoforms in Drosophila models of Spinocerebellar Ataxia Type 3. Johnson SL; Blount JR; Libohova K; Ranxhi B; Paulson HL; Tsou WL; Todi SV Neurobiol Dis; 2019 Dec; 132():104535. PubMed ID: 31310802 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]